Cardiol Therapeutics (CRDL) vs LENZ Therapeutics (LENZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 11.3% versus a loss of 90.0%. Over five years, CRDL leads with a -60.1% price change compared with -95.6% for LENZ. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $93.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | LENZ |
|---|---|---|
| Share price | $0.8626 | $2.97 |
| Market cap | $110.14M | $93.16M |
| 1-day change | -2.28% | -11.23% |
| YTD return | -9.58% | -81.47% |
| 1-year return | -11.35% | -89.97% |
| 5-year return | -60.06% | -95.57% |
| EPS (TTM) | $-0.24 | $-4.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $19.09M |
| Net income (latest FY) | — | $-82.13M |
| Gross margin | — | 97.81% |
| Operating margin | — | -477.46% |
| Net margin | — | -430.25% |
| 52-week high | $2.34 | $32.13 |
| 52-week low | $0.8417 | $2.80 |
| Distance from 52-week high | -63.14% | -90.77% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +874.96% | +400.17% |
| Average volume | 1.20M | 892.30K |
| Shares outstanding | 127.69M | 31.42M |
| Employees | 18 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed LENZ by 78.6 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
CRDL vs LENZ FAQ
Which is bigger, Cardiol Therapeutics or LENZ Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $93.16M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, CRDL or LENZ?
CRDL returned -11.35% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and LENZ Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.